2-chloroethyl-3-sarcosinamide-1-nitrosourea

DB11688InvestigationalSmall molecule

2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal Cancer, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.

Formula / weight: C₆H₁₁ClN₄O₃ · 222.63 g/mol (avg)
Also known as: ACETAMIDE, 2-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)METHYLAMINO)- · SarCNU · SARCOSINEAMIDE CHLOROETHYLNITROSOUREA · Sarmustine
Code names: NSC-364432

Resolves to

Compound

UNIIBHB013S3MOCAS81965-43-7ChEMBLCHEMBL166937PubChem100773

Structure

InChIKeyHYHJFNXFVPGMBI-UHFFFAOYSA-NSMILESCN(CC(N)=O)C(=O)N(CCCl)N=O

Transporters

O75751SLC22A3

What you can answer from here — as of July 07, 2026

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

39Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of 2-chloroethyl-3-sarcosinamide-1-nitrosourea, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account